Sartorius Stedim Biotech Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Rene Faber

Chief executive officer

€790.0k

Total compensation

CEO salary percentage	68.4%
CEO tenure	1.7yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rene Faber's remuneration changed compared to Sartorius Stedim Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	€161m
Jun 30 2024	n/a	n/a	€170m
Mar 31 2024	n/a	n/a	€255m
Dec 31 2023	€790k	€540k	€310m
Sep 30 2023	n/a	n/a	€460m
Jun 30 2023	n/a	n/a	€635m
Mar 31 2023	n/a	n/a	€717m
Dec 31 2022	€578k	€288k	€876m
Sep 30 2022	n/a	n/a	€681m
Jun 30 2022	n/a	n/a	€625m
Mar 31 2022	n/a	n/a	€559m
Dec 31 2021	€901k	€396k	€414m
Sep 30 2021	n/a	n/a	€523m
Jun 30 2021	n/a	n/a	€469m
Mar 31 2021	n/a	n/a	€398m
Dec 31 2020	€742k	€396k	€336m
Sep 30 2020	n/a	n/a	€299m
Jun 30 2020	n/a	n/a	€255m
Mar 31 2020	n/a	n/a	€254m
Dec 31 2019	€784k	€425k	€235m

Compensation vs Market: Rene's total compensation ($USD831.67K) is below average for companies of similar size in the UK market ($USD5.74M).

Compensation vs Earnings: Rene's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Rene Faber (49 yo)

1.7yrs

Tenure

€790,000

Compensation

Dr. Rene Faber serves as Head of Bioprocess Solutions Division and Member of the Executive Board at Sartorius Aktiengesellschaft since January 01, 2019. He serves as Chief Executive Officer at Sartorius St...

Board Members

Name	Position	Tenure	Compensation	Ownership
Rene Faber	CEO & DIrector	5.7yrs	€790.00k	no data
Joachim Kreuzburg	Non-Executive & Non-Independent Chairman	17.4yrs	€693.15k	0.000010% € 1.6k
Lothar Kappich	Director	7.2yrs	€84.00k	0% € 0
Henri Riey	Director	17.4yrs	€56.00k	0.000010% € 1.6k
Pascale Boissel	Independent Director	5.7yrs	€93.00k	0% € 0
Anne-Marie Graffin	Lead Independent Director	9.6yrs	€91.00k	0.000010% € 1.6k
Susan Dexter	Independent Director	9.6yrs	€84.00k	0.000010% € 1.6k
Romaine Fernandes	Employee Representative Non - Executive Director	1.1yrs	no data	0% € 0

8.4yrs

Average Tenure

61yo

Average Age

Experienced Board: DIMP's board of directors are considered experienced (8.4 years average tenure).

Sartorius Stedim Biotech Management

Management criteria checks 2/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Less than half of directors are independent

Recent updates

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025

Insufficient new directors

Investor sentiment deteriorates as stock falls 27%

Insufficient new directors

Upcoming dividend of €0.69 per share

New minor risk - Profit margin trend

Dividend of €0.69 announced

Insufficient new directors

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has completed a Follow-on Equity Offering in the amount of €1.2 billion.

Insufficient new directors

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 15%

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Less than half of directors are independent

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €362

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age